This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Biocrine Ab. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Ingo Leibiger: Innovator in Diabetes Research
Introduction
Ingo Leibiger is a notable inventor based in Solna, Sweden. He has made significant contributions to the field of diabetes research, particularly in understanding insulin resistance, which is a central feature of type II diabetes. His work has implications for the treatment of this prevalent condition.
Latest Patents
Ingo Leibiger holds a patent for a "Mechanism for identifying drugs for the treatment of type II diabetes." This patent addresses the complexities of insulin signaling, which is mediated by a network of pathways involving various proteins and isoforms. His research demonstrates that secreted insulin plays a crucial role in the activation of the glucokinase gene in pancreatic beta cells, highlighting the selectivity of insulin action through different isoforms of the Insulin Receptor.
Career Highlights
Leibiger's career is marked by his dedication to advancing the understanding of insulin's role in diabetes. His innovative approach has led to the development of new mechanisms that could potentially improve treatment options for patients suffering from type II diabetes.
Collaborations
Ingo Leibiger has collaborated with esteemed colleagues such as Per-Olof Berggren and Barbara Leibiger. These partnerships have enriched his research and contributed to the advancement of knowledge in the field of diabetes.
Conclusion
Ingo Leibiger's work exemplifies the intersection of innovation and medical research. His contributions to understanding insulin resistance are vital for developing effective treatments for type II diabetes. His patent and collaborative efforts continue to influence the field positively.